Immunic appoints biopharmaceutical executive Jon Congleton to board

Group 1 - The content provided by the Company is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities [1] - The Company receives annual cash compensation of up to $25,000 for publishing services rendered on behalf of Immunic Inc [2]